Publications by authors named "Olga Gallardo"

5 Publications

  • Page 1 of 1

A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version.

Value Health 2011 Sep-Oct;14(6):859-61. Epub 2011 May 28.

Digestive Disease Unit, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain.

Objectives: The Work Productivity and Activity Impairment Questionnaire (WPAI) is an instrument that measures work impairment in the setting of different diseases. One previous study validating the WPAI in Crohn's disease (CD) patients suggested that its reproducibility may be unsatisfactory. This study evaluated the validity and reproducibility of the Spain Spanish version of the WPAI questionnaire in CD patients.

Methods: In a prospective study, convergent validity was tested comparing WPAI with quality of life and CD activity indices. Known-groups validity was assessed by comparing WPAI scores in CD patients with active versus inactive disease. Reproducibility of repeated tests was evaluated by comparing two WPAI measures obtained two to four weeks apart in stable patients.

Results: One hundred eight patients were included in the various steps of the analysis. The WPAI showed adequate known groups validity and convergent validity. The reproducibility of the test and, specifically, that of the evaluation of presenteeism (the impairment of productivity while working) were good.

Conclusions: This study confirms the validity of WPAI for measuring work impairment in CD patients. In contrast to previous studies, the test reproducibility was adequate.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2011.02.1179DOI Listing
November 2011

Development and validation of the Crohn's disease perceived work disability questionnaire.

Inflamm Bowel Dis 2011 Nov 1;17(11):2350-7. Epub 2011 Feb 1.

Digestive Diseases Unit, Hospital de Sabadell, Institut Universitari Parc Taulí, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: No validated instruments have been developed to measure work disability in Crohn's disease (CD). The aim of our study was to develop and validate a CD perceived work disability questionnaire (CPWDQ).

Methods: Development phase: an initial questionnaire containing 52 items was obtained from patients' interviews plus additional sources; it was completed by 106 patients and the 16 most significant items were selected using a psychometric method in order to create the CPWDQ. Validation phase: The validation assessed the questionnaire's convergent validity, discriminant validity, test-retest reproducibility, and internal consistency in 108 patients. Spearman rank correlation, t-test, intraclass correlation, and Cronbach's alpha were used for the analysis.

Results: Convergent validity was confirmed by good correlations between the CPWDQ and: clinical activity (r = 0.59, P < 0.01), the Short Inflammatory Bowel Disease Questionnaire, IBDQ-9, (r = 0.76, P < 0.001), Euroqol-5D (r = 0.53, P < 0.01), and overall work impairment (WPAI_CD) r = 0.66 (P < 0.01). Discriminant validity: CPWQ scores were higher in patients expected to have more severe disability, that is, in patients with active disease (n = 38) 32.3 ± 7.3 versus inactive (n = 70) 22.6 ± 5.9 (P < 0.001), in those requiring previous sick leave 30.7 ± 7.5 (n = 45) versus no sick leave 22.6 ± 6.6 (n = 63) (P < 0.01), and in those requiring hospitalization 32.2 ± 8.6 (n = 18) versus no hospitalization 24.7 ± 7.1 (n = 90) (P < 0.01). Internal consistency was also good (Cronbach's alpha = 0.89). Reproducibility: CPWDQ measures obtained 2 weeks apart showed an excellent intraclass correlation coefficient: 0.89 (95% CI: 0.83-0.93).

Conclusions: The CPWDQ seems to be a valid, reliable tool for measuring subjective work disability in CD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.21604DOI Listing
November 2011

Analysis of court criteria for awarding disability benefits to patients with Crohn's disease.

Clin Gastroenterol Hepatol 2009 Dec 4;7(12):1322-7. Epub 2009 Feb 4.

Digestive Diseases Unit, Hospital de Sabadell, Institut Universitari Parc Taulí, Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain.

Background & Aims: Chronic disability and its consequences for social life and employment are important but often neglected aspects of Crohn's disease. No specific scores have been developed to evaluate chronic disability in patients with Crohn's disease; the medical criteria used by government authorities to award disability benefits have not been analyzed. We aimed to determine the courts' criteria for awarding disability benefits to patients with Crohn's disease in Spain.

Methods: We systematically searched case law databases in Spain's regional Supreme Courts to identify sentences regarding awards of disability benefits to patients with Crohn's disease. Selected decisions were reviewed to extract variables related to the awarding of benefits. Univariate and multivariate analyses were performed to determine which variables predicted the awarding of benefits.

Results: Two hundred eighty sentences were reviewed. The rate of judicial decisions in favor of the claimants varied considerably between the various tribunals. Multivariate analysis showed that adequate description of the disease (odds ratio, 8.6), fecal incontinence (odds ratio, 8.9), the number of associated diseases (odds ratio, 2.3), and the presence of an ostomy (odds ratio, not estimable) were independent predictors of the awarding of Social Security benefits.

Conclusions: The amount of Social Security benefits awarded to patients with Crohn's disease varied depending on the tribunal. The most important predictors of a court's disability award were the adequate description of the patient's disease, fecal incontinence, associated diseases, and presence of an ostomy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2009.01.015DOI Listing
December 2009

Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version.

Eur J Gastroenterol Hepatol 2009 Jul;21(7):809-15

Digestive Disease Unit, Sabadell's Hospital, Autonomous Barcelona University, Barcelona, Spain.

Background: The Work Productivity and Activity Impairment questionnaire has only been partially validated in Crohn's disease.

Objective: To test the Work Productivity and Activity Impairment questionnaire for use in Crohn's disease patients.

Methods: A validated Spanish translation of the test was assessed. 'Discriminant validity' was evaluated by comparing Work Productivity and Activity Impairment scores in Crohn's disease patients with active versus inactive disease, and in patients versus healthy controls. 'Convergent validity' was tested comparing Work Productivity and Activity Impairment questionnaire with quality of life, Crohn's disease activity index and a debriefing questionnaire. 'Reproducibility' of repeated tests was evaluated by comparing two Work Productivity and Activity Impairment measures obtained 2 weeks apart in stable patients. 'Responsiveness' was determined by comparing Work Productivity and Activity Impairment values in the same patients during a flare-up of Crohn's disease and during remission. The Wilcoxon test for paired data and the Mann-Whitney U test for unpaired data were used for comparisons.

Results: One hundred and six patients were included in the various steps of the analysis. All Work Productivity and Activity Impairment parameters showed adequate discriminant and convergent validity and responsiveness. The test's reproducibility was also adequate, except for the evaluation of presenteeism (the impairment of productivity while working).

Conclusion: The Spanish Work Productivity and Activity Impairment questionnaire is a valid and reliable measurement of work impairment in Crohn's disease. Unexpectedly, the test did not present satisfactory reproducibility for the evaluation of presenteeism. The reliability of this last finding should be evaluated in further studies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0b013e32830f4c9eDOI Listing
July 2009

Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease.

Inflamm Bowel Dis 2006 Aug;12(8):692-6

Unitat de Malalties Digestives, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.

Background: Thiopurinic immunomodulators are effective for maintaining symptom remission in Crohn's disease. Little is known, however, about their effect on patients' quality of life or psychological well-being. The present study aimed to determine whether remission induced by thiopurinic immunomodulators returns levels of quality of life and psychological well-being to normal.

Materials And Methods: A case-control study was performed. Cases were 33 patients with Crohn's disease treated with azathioprine or 6-mercaptopurine and in stable remission for at least 6 months. Sixty-six healthy individuals matched 2:1 by age and sex and 14 patients with active Crohn's disease were included as control groups. Quality of life was evaluated with the Short Form (SF-36) questionnaire, and the respective Hamilton rating scales were used for anxiety and depression. ANOVA with Bonferroni's correction was used for multiple comparisons.

Results: SF-36 global scores were 85 in the study group, 85 in healthy controls (P = 1), and 58.6 in patients with active disease (P < 0.001 for the comparison with the other 2 groups). The differences between values were 0 (95% CI -4-4), 26.4 (95% CI 20-32), and 26.4 (95% CI 19-33), respectively. The respective anxiety and depression scores were 6.5, 5.5, and 16.2 and 3.7, 3.3, and 10.9. No significant differences were observed in any of the SF-36 domains between case and control groups, whereas in patients with active disease, all domains were significantly worse.

Conclusions: Thiopurinic immunomodulator-induced remission restores normal levels of quality of life and psychological well-being in Crohn's disease patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/00054725-200608000-00004DOI Listing
August 2006